Elanco Animal HealthELAN
About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Employees: 9,800
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
148% more call options, than puts
Call options by funds: $44.8M | Put options by funds: $18M
58% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 50
12% more repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 121
8% more funds holding
Funds holding: 369 [Q1] → 398 (+29) [Q2]
0.06% less ownership
Funds ownership: 97.68% [Q1] → 97.61% (-0.06%) [Q2]
11% less capital invested
Capital invested by funds: $7.83B [Q1] → $6.96B (-$871M) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Barclays Balaji Prasad 53% 1-year accuracy 16 / 30 met price target | 71%upside $22 | Overweight Maintained | 23 Sept 2024 |
Stifel Jonathan Block 46% 1-year accuracy 12 / 26 met price target | 56%upside $20 | Buy Reiterated | 19 Sept 2024 |
Morgan Stanley Erin Wright 57% 1-year accuracy 12 / 21 met price target | 17%upside $15 | Equal-Weight Downgraded | 19 Sept 2024 |
Financial journalist opinion
Based on 145 articles about ELAN published over the past 30 days